Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of glyburide in healthy subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Jul 2011
At a glance
- Drugs Saxagliptin (Primary) ; Glibenclamide
- Indications Type 2 diabetes mellitus
- Focus Pharmacokinetics
- 22 Jun 2011 New trial record